The fact that PKG inhibition significantly reduces this type of degeneration could, thus, indicate that PKG inhibitors may be applicable even more broadly in neurodegenerative conditions characterized by axonal damage, such as spinal cord injury or multiple sclerosis. Here, PRKG1 is linked to multiple sclerosis.